| human | Q5 |
| P496 | ORCID iD | 0000-0002-8885-4718 |
| P1153 | Scopus author ID | 13605409400 |
| P166 | award received | Fellow of the American Heart Association | Q105670306 |
| Special Recognition Award in Thrombosis | Q124962476 | ||
| P735 | given name | ??? | Q17501985 |
| ??? | Q17501985 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q51007360 | ADAMTS13 Retards Progression of Diabetic Nephropathy by Inhibiting Intrarenal Thrombosis in Mice. |
| Q36166160 | ADAMTS13 reduces VWF-mediated acute inflammation following focal cerebral ischemia in mice. |
| Q38257983 | AGXT2: a promiscuous aminotransferase |
| Q35911222 | Alternatively-spliced extra domain A of fibronectin promotes acute inflammation and brain injury after cerebral ischemia in mice. |
| Q81638978 | Another lesson from the factor V Leiden mouse: thrombin generation drives arterial disease |
| Q44102064 | Anticoagulant responses to thrombin are enhanced during regression of atherosclerosis in monkeys. |
| Q52680907 | Antiphospholipid Antibodies and Recurrent Thrombosis after a First Unprovoked Venous Thromboembolism. |
| Q46973322 | ApoA-I: a missing link between homocysteine and lipid metabolism? |
| Q43088590 | Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa |
| Q35101870 | Case report: paroxysmal cold hemoglobinuria presenting during pregnancy. |
| Q35607298 | Cellular fibronectin containing extra domain A promotes arterial thrombosis in mice through platelet Toll-like receptor 4 |
| Q80382250 | Cerebral vascular dysfunction during hypercholesterolemia |
| Q44922534 | Cerebral vascular dysfunction mediated by superoxide in hyperhomocysteinemic mice. |
| Q45879180 | Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity |
| Q45868176 | Clinical and laboratory phenotype variability in type 2M von Willebrand disease |
| Q36920462 | Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States |
| Q53654430 | Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A. |
| Q54151583 | Consequences of hyperhomocyst(e)inemia on vascular function in atherosclerotic monkeys. |
| Q42535713 | Countervailing effects on atherogenesis and plaque stability: a paradoxical benefit of hypercoagulability? |
| Q36407225 | Critical role for the mitochondrial permeability transition pore and cyclophilin D in platelet activation and thrombosis |
| Q38847437 | D-dimer levels and recurrence in patients with unprovoked VTE and a negative qualitative D-dimer test after treatment |
| Q50595629 | D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. |
| Q27342329 | Deficiency of superoxide dismutase impairs protein C activation and enhances susceptibility to experimental thrombosis |
| Q36348620 | Deficiency of superoxide dismutase promotes cerebral vascular hypertrophy and vascular dysfunction in hyperhomocysteinemia |
| Q36326913 | Deletion of Methionine Sulfoxide Reductase A Does Not Affect Atherothrombosis but Promotes Neointimal Hyperplasia and Extracellular Signal-Regulated Kinase 1/2 Signaling. |
| Q53205345 | Dok-1 negatively regulates platelet integrin αIIbβ3 outside-in signalling and inhibits thrombosis in mice. |
| Q36837948 | Dominant negative PPARγ promotes atherosclerosis, vascular dysfunction, and hypertension through distinct effects in endothelium and vascular muscle |
| Q84039989 | Durable responses to rituximab in acquired factor VIII deficiency |
| Q44117642 | Effect of hyperhomocysteinemia on protein C activation and activity |
| Q51279986 | Effect of mechanical ventilation on carotid artery thrombosis induced by photochemical injury in mice. |
| Q71550470 | Effects of 1,2-dimethoxyethane on the catalytic and coenzyme properties of glycogen phosphorylase |
| Q74152486 | Electronic communication at arteriosclerosis, thrombosis, and vascular biology |
| Q27342480 | Endothelial PPAR-γ Protects Against Vascular Thrombosis by Downregulating P-Selectin ExpressionSignificance |
| Q43633770 | Endothelial dysfunction and elevation of S-adenosylhomocysteine in cystathionine beta-synthase-deficient mice. |
| Q42123941 | Enhanced susceptibility to arterial thrombosis in a murine model of hyperhomocysteinemia. |
| Q45884927 | Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. |
| Q38338187 | Equilibrium binding of thrombin to recombinant human thrombomodulin: effect of hirudin, fibrinogen, factor Va, and peptide analogues. |
| Q40493212 | Expression of TNF-related apoptosis-inducing ligand (TRAIL) in megakaryocytes and platelets |
| Q28508801 | Expression of thrombomodulin and consequences of thrombomodulin deficiency during healing of cutaneous wounds |
| Q43847718 | Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor-cleaving protease activity. |
| Q33834495 | Fetal hemorrhage and platelet dysfunction in SLP-76-deficient mice. |
| Q47554675 | Fibronectin Containing Extra Domain A Induces Plaque Destabilization in the Innominate Artery of Aged Apolipoprotein E-Deficient Mice |
| Q36201783 | Fibronectin Splicing Variants Containing Extra Domain A Promote Atherosclerosis in Mice Through Toll-Like Receptor 4. |
| Q91788900 | Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A |
| Q36359605 | Genetic Ablation of Extra Domain A of Fibronectin in Hypercholesterolemic Mice Improves Stroke Outcome by Reducing Thrombo-Inflammation |
| Q38867357 | Genetic testing to guide warfarin dosing: Impact of direct oral anticoagulants. |
| Q35115036 | Glutathione peroxidase-1 plays a major role in protecting against angiotensin II-induced vascular dysfunction. |
| Q60696825 | Haemophilia clinical care and research needs: Assessing priorities |
| Q90423789 | Helicopter "Drip and Ship" Flights Do Not Alter the Pharmacological Integrity of rtPA |
| Q40911244 | Homocysteine and vascular dysfunction. |
| Q28365886 | Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways |
| Q30652065 | Hydrogen peroxide promotes aging-related platelet hyperactivation and thrombosis |
| Q79774410 | Hyperhomocysteinemia increases arterial permeability and stiffness in mice |
| Q35603940 | Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA. |
| Q46923093 | Hypermethylation of Fads2 and altered hepatic fatty acid and phospholipid metabolism in mice with hyperhomocysteinemia. |
| Q36402513 | Hypomorphic mutations in TRNT1 cause retinitis pigmentosa with erythrocytic microcytosis. |
| Q77974687 | Impaired anticoagulant response to infusion of thrombin in atherosclerotic monkeys associated with acquired defects in the protein C system |
| Q46902318 | Influence of folate on arterial permeability and stiffness in the absence or presence of hyperhomocysteinemia. |
| Q45855075 | Interim results from a large multinational extension trial (guardian(™) 2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A. |
| Q37317725 | Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site |
| Q45870641 | Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors |
| Q45876675 | Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight(®) ) in previously treated patients with severe haemophilia A: interim results of the guardian(™) 2 extension trial |
| Q58606959 | Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial |
| Q41616739 | Malate dehydrogenase: isolation from E. coli and comparison with the eukaryotic mitochondrial and cytoplasmic forms. |
| Q36208958 | Mechanisms of the atherogenic effects of elevated homocysteine in experimental models. |
| Q35653311 | Mechanisms of thrombosis in obesity |
| Q36952316 | Murine models of hyperhomocysteinemia and their vascular phenotypes |
| Q40757976 | Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4). |
| Q48115372 | On PAR with aPC to target inflammasomes. |
| Q92002729 | Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial) |
| Q46862730 | Overexpression of dimethylarginine dimethylaminohydrolase inhibits asymmetric dimethylarginine-induced endothelial dysfunction in the cerebral circulation. |
| Q30493459 | Overexpression of dimethylarginine dimethylaminohydrolase protects against cerebral vascular effects of hyperhomocysteinemia. |
| Q73062428 | Platelet factor 4 enhances generation of activated protein C in vitro and in vivo |
| Q89052133 | Prospective, multicenter study of postoperative deep-vein thrombosis in patients with haemophilia undergoing major orthopaedic surgery |
| Q52757771 | Prostaglandin E1 and Its Analog Misoprostol Inhibit Human CML Stem Cell Self-Renewal via EP4 Receptor Activation and Repression of AP-1. |
| Q34203276 | Protective vascular and cardiac effects of inducible nitric oxide synthase in mice with hyperhomocysteinemia |
| Q27333918 | Protein methionine oxidation augments reperfusion injury in acute ischemic stroke |
| Q40158925 | Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. |
| Q79326633 | Prothrombotic effects of hyperhomocysteinemia and hypercholesterolemia in ApoE-deficient mice |
| Q70561969 | Recurrent neuroendocrine (Merkel cell) carcinoma of the skin presenting as marrow failure in a man with systemic lupus erythematosus |
| Q26865448 | Regulation of thrombosis and vascular function by protein methionine oxidation |
| Q77108833 | Remission after 13-cis retinoic acid in thrombotic thrombocytopenic purpura |
| Q45887360 | Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. |
| Q35848141 | Role of FcRgamma and factor XIIIA in coated platelet formation |
| Q35831223 | Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. |
| Q78290384 | Role of the adapter protein SLP-76 in GPVI-dependent platelet procoagulant responses to collagen |
| Q35023255 | Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials. |
| Q28590182 | Structure of cerebral arterioles in cystathionine beta-synthase-deficient mice |
| Q31956669 | Supplementation of atherogenic diet with B vitamins does not prevent atherosclerosis or vascular dysfunction in monkeys. |
| Q51797126 | Testosterone regulation of renal cystathionine beta-synthase: implications for sex-dependent differences in plasma homocysteine levels. |
| Q81888031 | The benefits of excess EPCR |
| Q43236874 | The homocysteine paradox. |
| Q33770105 | The nutrigenetics of hyperhomocysteinemia: quantitative proteomics reveals differences in the methionine cycle enzymes of gene-induced versus diet-induced hyperhomocysteinemia |
| Q31115372 | The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors: a post hoc exploratory analysis of recombinant activated factor VII data [...] |
| Q45873319 | The small molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis |
| Q39011285 | Thrombosis in the setting of obesity or inflammatory bowel disease. |
| Q39027731 | Thrombosis in the setting of obesity or inflammatory bowel disease. |
| Q78773970 | Thrombosis of vein grafts: wall tension restrains thrombomodulin expression |
| Q46495749 | Tissue-specific changes in H19 methylation and expression in mice with hyperhomocysteinemia. |
| Q36844696 | Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia. |
| Q43100173 | Trends in clinical laboratory homocysteine testing from 1997 to 2010: the impact of evidence on clinical practice at a single institution. |
| Q91953491 | Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials |
| Q51612797 | Von Willebrand Factor--A Rapid Sensor of Paravalvular Regurgitation during TAVR? |
Search more.